Triggering FCα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5954-5961

  Stockmeyer, B ^a   Dechant, M ^a   Van Egmond, M ^a   Tutt, A L ^a   Sundarapandiyan, K ^a   Graziano, R F ^a   Repp, R ^a   Kalden, J R ^a   Gramatzki, M ^a   Glennie, M J ^a   Van de Winkel, J G J ^a   Valerius, T ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD20 ANTIGEN; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0034670004     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5954     Document Type: Article

References (41)

1. Cancer undefeated
2. Treatment of non-Hodgkin's lymphoma
3. Continuous cultures of fused cells secreting antibody of predefined specificity
4. Monoclonal antibody-based therapies of leukemia and lymphoma
5. CD20: A regulator of cell- cycle progression of B lymphocytes
6. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
7. Fc receptors
8. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
9. Fc receptors are required in passive and active immunity to melanoma
10. Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma
11. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens
12. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
13. Cytokines, tumour-cell death and immunogenicity: A question of choice
14. Preclinical studies with FcγR I bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer
15. Neutrophils express the high affinity receptor for IgG (FcγRI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
16. Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy
17. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
18. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells
19. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
20. Immunotherapeutic potential of bispecific antibodies
21. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy
22. Structure and function of human IgA Fc receptors (FcαR)
23. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice
24. Human immunoglobulin A receptor (FcαRI, CD89) function in transgenic mice requires both FcR γ-chain and CR3 (CD11b/CD18)
25. Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy
26. Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets
27. 3 antibody derivates
28. Chemically engineered chimeric and multi-Fab antibodies
29. Functional analysis of human FcγRII (CD32) isoforms expressed in B lymphocytes
30. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
31. Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood
32. The molecular dissection of Fcγ receptor mediated phagocytosis
33. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR γ-chain: Molecular basis for CD89/FcR γ-chain association
34. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo
35. Antigen and Fc receptor signaling: The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM)
36. Serial triggering of TCRs: A basis for the sensitivity and specificity of antigen recognition
37. The specificity of the human neutrophil IgA receptor (FcαR) determined by measurement of chemiluminescence induced by serum or secretory IgA1 or IgA2
38. IgM monoclonal antibodies recognizing FcαR but not FcγRIII trigger a respiratory burst in neutrophils although both trigger an increase in intracellular calcium levels and degranulation
39. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
40. Phase II trial of the bispecific antibody MDX-H210 (anti-HER-2/neu X anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER-2/neu
41. Phase I trial of bispecific antibody MDX-H210 (FcγRI X HER-2/NEU) in combination with G-CSF in patients with stage IV metastatic breast cancer